Roche Holding Ltd. (ROG) Stock Rating Reaffirmed by JPMorgan Chase & Co.
Roche Holding Ltd. (VTX:ROG)‘s stock had its “buy” rating restated by stock analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday.
ROG has been the subject of a number of other research reports. Citigroup Inc. reissued a “buy” rating on shares of Roche Holding in a report on Thursday, June 23rd. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Roche Holding in a report on Tuesday, July 19th.
Roche Holding (VTX:ROG) opened at 238.30 on Monday. The stock’s 50 day moving average price is CHK 241.71 and its 200 day moving average price is CHK 245.92. The company has a market cap of CHK 203.07 billion and a PE ratio of 21.85. Roche Holding has a 12-month low of CHK 229.90 and a 12-month high of CHK 281.40.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/roche-holding-ltd-rog-stock-rating-reaffirmed-by-jpmorgan-chase-co-2.html
About Roche Holding
Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.